This Atypical Hemolytic Uremic Syndrome (aHUS)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome trends in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Study Period: 2019-2032
The 's Atypical Hemolytic Uremic Syndrome epidemiology report gives a thorough understanding of atypical hemolytic uremic syndrome. Atypical Hemolytic Uremic Syndrome (aHUS) is defined as a rare cause of thrombotic microangiopathy (TMA), characterized by micro-angiopathic hemolytic anemia, consumptive thrombocytopenia, and multisystem end organ involvement, most commonly affecting the kidney.
Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or occur for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder. Unlike individuals with typical HUS, who usually recover from the life-threatening initial episode and usually respond well to supportive treatment, individuals with aHUS are much more likely to develop serious chronic complications such as severe high blood pressure (hypertension) and kidney (renal) failure.
aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.
Hemolytic Uremic Syndrome (HUS) is one of the disorders that belong to the spectrum of thrombotic microangiopathy (TMA). TMAs are a group of life-threatening diseases characterized by endothelial dysfunction and the presence of thrombi in small blood vessels. As the thrombus forms, there is the consumption of platelets and mechanical disruption of erythrocytes, which leads to thrombocytopenia and microangiopathic hemolytic anemia. Vessel occlusion results in tissue ischemia and organ damage, mainly affecting the kidneys, although other organs can be involved.
Diagnosing aHUS is complicated by the fact that it is more difficult to establish without a family history of the disorder. The diagnostic criteria associated with aHUS are hemolytic anemia (anemia in the presence of broken red blood cells), low platelet count (thrombocytopenia), and kidney dysfunction.
Most of the time, aHUS does not present with initial severe symptoms. The initial onset will most likely appear to be flu-like, with lethargic behavior, pale color, and a loss of appetite. It has been experienced that adult hospitals may often send the patient home with a flu diagnosis, while children's hospitals may do a blood draw and conduct basic tests, such as Hemoglobin, Hematocrit, white blood cell counts, and platelet counts.
After initial blood tests, the hospital may conduct creatinine and BUN tests and may (or may not) reach an initial diagnosis of aHUS. The flu-like symptoms described above will continue to worsen when episodes are active. At this point, kidney function may begin to fall, often quite dramatically. Other organs sometimes experience problems in some cases. Quite often, seizures have been reported, along with other neurological issues. Sometimes gastronomical problems occur as well.
aHUS is a diagnosis of exclusion, ruling out (STEC) infection and other secondary causes of TMA , including (TTP). To exclude TTP, a blood test that measures the level of a protein called ADAMTS13 is used. The diagnostic tests for aHUS include blood tests (CBC and eGFR), specific test to differ from TTP, and genetic testing.
The epidemiology section provides insights about the historical and current Atypical Hemolytic Uremic Syndrome patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology scenario in the 7MM covering the United States, EU-5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total prevalent cases of Atypical Hemolytic Uremic Syndrome were 7,042 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology [segmented as Total Prevalent Cases of Atypical hemolytic uremic syndrome, Total Diagnosed Cases of Atypical hemolytic uremic syndrome, Total Age group-specific Cases of Atypical hemolytic uremic syndrome, and Total Treated Cases of Atypical hemolytic uremic syndrome] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Atypical Hemolytic Uremic Syndrome epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current Atypical Hemolytic Uremic Syndrome patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Atypical Hemolytic Uremic Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Geography Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Atypical Hemolytic Uremic Syndrome (aHUS) Understanding
The 's Atypical Hemolytic Uremic Syndrome epidemiology report gives a thorough understanding of atypical hemolytic uremic syndrome. Atypical Hemolytic Uremic Syndrome (aHUS) is defined as a rare cause of thrombotic microangiopathy (TMA), characterized by micro-angiopathic hemolytic anemia, consumptive thrombocytopenia, and multisystem end organ involvement, most commonly affecting the kidney.
Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or occur for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder. Unlike individuals with typical HUS, who usually recover from the life-threatening initial episode and usually respond well to supportive treatment, individuals with aHUS are much more likely to develop serious chronic complications such as severe high blood pressure (hypertension) and kidney (renal) failure.
aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.
Hemolytic Uremic Syndrome (HUS) is one of the disorders that belong to the spectrum of thrombotic microangiopathy (TMA). TMAs are a group of life-threatening diseases characterized by endothelial dysfunction and the presence of thrombi in small blood vessels. As the thrombus forms, there is the consumption of platelets and mechanical disruption of erythrocytes, which leads to thrombocytopenia and microangiopathic hemolytic anemia. Vessel occlusion results in tissue ischemia and organ damage, mainly affecting the kidneys, although other organs can be involved.
Diagnosing aHUS is complicated by the fact that it is more difficult to establish without a family history of the disorder. The diagnostic criteria associated with aHUS are hemolytic anemia (anemia in the presence of broken red blood cells), low platelet count (thrombocytopenia), and kidney dysfunction.
Most of the time, aHUS does not present with initial severe symptoms. The initial onset will most likely appear to be flu-like, with lethargic behavior, pale color, and a loss of appetite. It has been experienced that adult hospitals may often send the patient home with a flu diagnosis, while children's hospitals may do a blood draw and conduct basic tests, such as Hemoglobin, Hematocrit, white blood cell counts, and platelet counts.
After initial blood tests, the hospital may conduct creatinine and BUN tests and may (or may not) reach an initial diagnosis of aHUS. The flu-like symptoms described above will continue to worsen when episodes are active. At this point, kidney function may begin to fall, often quite dramatically. Other organs sometimes experience problems in some cases. Quite often, seizures have been reported, along with other neurological issues. Sometimes gastronomical problems occur as well.
aHUS is a diagnosis of exclusion, ruling out (STEC) infection and other secondary causes of TMA , including (TTP). To exclude TTP, a blood test that measures the level of a protein called ADAMTS13 is used. The diagnostic tests for aHUS include blood tests (CBC and eGFR), specific test to differ from TTP, and genetic testing.
Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology
The epidemiology section provides insights about the historical and current Atypical Hemolytic Uremic Syndrome patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology scenario in the 7MM covering the United States, EU-5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total prevalent cases of Atypical Hemolytic Uremic Syndrome were 7,042 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology [segmented as Total Prevalent Cases of Atypical hemolytic uremic syndrome, Total Diagnosed Cases of Atypical hemolytic uremic syndrome, Total Age group-specific Cases of Atypical hemolytic uremic syndrome, and Total Treated Cases of Atypical hemolytic uremic syndrome] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology
The epidemiology segment also provides the Atypical Hemolytic Uremic Syndrome epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL-Views
To keep up with the current Atypical Hemolytic Uremic Syndrome patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Atypical Hemolytic Uremic Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
- The report covers the descriptive overview of Atypical Hemolytic Uremic Syndrome, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Atypical Hemolytic Uremic Syndrome.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM total prevalent cases of Atypical Hemolytic Uremic Syndrome, total diagnosed cases of Atypical Hemolytic Uremic Syndrome, total age group-specific cases of Atypical Hemolytic Uremic Syndrome in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Hemolytic Uremic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atypical Hemolytic Uremic Syndrome.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Atypical Hemolytic Uremic Syndrome (aHUS) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
Key Questions Answered
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Atypical Hemolytic Uremic Syndrome?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Atypical Hemolytic Uremic Syndrome patient pool in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Atypical Hemolytic Uremic Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Atypical Hemolytic Uremic Syndrome?
- Out of all 7MM countries, which country would have the highest prevalent population of Atypical Hemolytic Uremic Syndrome during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Atypical Hemolytic Uremic Syndrome Disease market
- To understand the future market competition in the Atypical Hemolytic Uremic Syndrome Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Atypical Hemolytic Uremic Syndrome Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Atypical Hemolytic Uremic Syndrome Disease market
- To understand the future market competition in the Atypical Hemolytic Uremic Syndrome Disease market
Table of Contents
1. Key Insights2. Report Introduction5. Epidemiology and Market Methodology11. Conclusion14. Patient Journey15. Unmet needs17. Publisher Capabilities18. Disclaimer19. About the Publisher
3. Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance
4. Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)
6. Disease Background and Overview
7. Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome
8. Diagnostic Guidelines
9. Current Treatment Practices of Atypical Hemolytic Uremic Syndrome
10. Treatment Guidelines
12. Epidemiology and Patient Population
13. Aypical Hemolytic Uremic Syndrome: Country-wise Epidemiology
16. Appendix
List of Tables
List of Figures
